group-women-sports-teams

Newsroom

Take a look inside our world

Press Releases

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy 

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
View all press releases

Our Stories

Teva scientist interacting with a large green abstract network graphic illustrating biological pathways and potential pathways for business growth. Leadership Global Operations Global Growth Biosimilars

Sustaining Teva’s Generics Powerhouse in the Acceleration Phase

 Teva scientist using microscope working on research for innovative medicines Leadership Research & Development Growth

Step Up Innovation

 Teva scientist looking at stylized DNA strand representing acceleration phase of pivot to growth strategy Leadership Research & Development Growth Innovation

Pivot to Growth: The Acceleration Phase

 Leadership Innovation Neuroscience Growth

Delivering on Growth Engines

 Innovation Growth

Teva in 2025: Innovation drives third consecutive year of growth

 Access to Medicine Sustainability Social Impact

Supporting Healthier Communities

 Evan Lippman, Teva’s Executive Vice President of Business Development Global Innovation Research & Development

“I Think People are Starting to Get That There’s a Lot of Upside at Teva”

 Global Innovation Research & Development Patient Focus

Teva Rise: Accelerating Pharma Innovation Globally

 Sustainability Impact

Using Antibiotics Wisely. Making Them Responsibly.

 Global Innovation Global Operations

Building the Factory of the Future with Augmented Reality

 View all stories

Contacts for Media Inquiries

United States

Email
 
Telephone

Israel & Corporate

Email
 
Telephone

Europe

Email

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com